Table of Contents
ISRN Gastroenterology
Volume 2013 (2013), Article ID 208073, 12 pages
http://dx.doi.org/10.1155/2013/208073
Review Article

Practical Medical Management of Crohn’s Disease

1Van Research and Training Hospital, Van 65300, Turkey
2Department of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Turkey

Received 1 July 2013; Accepted 1 September 2013

Academic Editors: L. Rodrigo and C.-T. Shun

Copyright © 2013 Bulent Baran and Cetin Karaca. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. R. Lichtenstein, S. B. Hanauer, W. J. Sandborn, and Practice Parameters Committee of American College of Gastroenterology, “Management of Crohn's disease in adults,” The American Journal of Gastroenterology, vol. 104, no. 2, pp. 465–483, 2009. View at Publisher · View at Google Scholar
  2. A. Dignass, G. van Assche, J. O. Lindsay et al., “The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 28–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Forrest, D. Symmons, and P. Foster, “Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?” Alimentary Pharmacology and Therapeutics, vol. 20, no. 10, pp. 1035–1043, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Takeuchi, S. Smale, P. Premchand et al., “Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 4, no. 2, pp. 196–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Kefalakes, T. J. Stylianides, G. Amanakis, and G. Kolios, “Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?” European Journal of Clinical Pharmacology, vol. 65, no. 10, pp. 963–970, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. D'Haens, F. Baert, G. van Assche et al., “Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial,” The Lancet, vol. 371, no. 9613, pp. 660–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Colombel, W. J. Sandborn, W. Reinisch et al., “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Beaugerie, P. Seksik, I. Nion-Larmurier, J. Gendre, and J. Cosnes, “Predictors of crohn's disease,” Gastroenterology, vol. 130, no. 3, pp. 650–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. F. Harvey and J. M. Bradshaw, “A simple index of Crohn's-disease activity,” The Lancet, vol. 1, no. 8167, p. 514, 1980. View at Google Scholar · View at Scopus
  10. G. van Assche, A. Dignass, J. Panes et al., “The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 7–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Seow, E. I. Benchimol, A. M. Griffiths, A. R. Otley, and A. H. Steinhart, “Budesonide for induction of remission in Crohn's disease,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD000296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. B. Hanauer and U. Strömberg, “Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials,” Clinical Gastroenterology and Hepatology, vol. 2, no. 5, pp. 379–388, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. Ford, S. V. Kane, K. J. Khan et al., “Efficacy of 5-aminosalicylates in crohn's disease: systematic review and meta-analysis,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 617–629, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. N. Bernstein, Z. Nugent, and J. F. Blanchard, “5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 731–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. J. Khan, T. A. Ullman, A. C. Ford et al., “Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 661–673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. C. Pearson, G. R. May, G. Fick, and L. R. Sutherland, “Azathioprine for maintaining remission of Crohn's disease,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD000067, 2000. View at Google Scholar · View at Scopus
  17. A. G. Fraser, “Methotrexate: first-line or second-line immunomodulator?” European Journal of Gastroenterology and Hepatology, vol. 15, no. 3, pp. 225–231, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Alfadhli, J. W. McDonald, and B. G. Feagan, “Methotrexate for induction of remission in refractory Crohn's disease,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003459, 2005. View at Google Scholar · View at Scopus
  19. J. M. Kremer, “Major side effects of low dose methotrexate,” in UpToDate, D. S. Basow, Ed., UpToDate, Waltham, Mass, USA, 2011. View at Google Scholar
  20. H. S. Te, T. D. Schiano, S. F. Kuan, S. B. Hanauer, H. S. Conjeevaram, and A. L. Baker, “Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 95, no. 11, pp. 3150–3156, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W. J. Sandborn, and J. Colombel, “Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials,” Clinical Gastroenterology and Hepatology, vol. 6, no. 6, pp. 644–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. R. Targan, S. B. Hanauer, S. J. H. van Deventer et al., “A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease,” The New England Journal of Medicine, vol. 337, no. 15, pp. 1029–1036, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. S. B. Hanauer, B. G. Feagan, G. R. Lichtenstein et al., “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial,” The Lancet, vol. 359, no. 9317, pp. 1541–1549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. S. B. Hanauer, W. J. Sandborn, P. Rutgeerts et al., “Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial,” Gastroenterology, vol. 130, no. 2, pp. 323–333, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. W. J. Sandborn, P. Rutgeerts, R. Enns et al., “Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 12, pp. 829–838, 2007. View at Google Scholar · View at Scopus
  27. W. J. Sandborn, S. B. Hanauer, P. Rutgeerts et al., “Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial,” Gut, vol. 56, no. 9, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. W. J. Sandborn, B. G. Feagan, S. Stoinov et al., “Certolizumab pegol for the treatment of Crohn's disease,” The New England Journal of Medicine, vol. 357, no. 3, pp. 228–238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Schreiber, M. Khaliq-Kareemi, I. C. Lawrance et al., “Maintenance therapy with certolizumab pegol for Crohn's disease,” The New England Journal of Medicine, vol. 357, no. 3, pp. 239–250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. van Hogezand, A. M. Witte, R. A. Veenendaal, M. J. Wagtmans, and C. B. Lamers, “Proximal Crohn's disease: review of the clinicopathologic features and therapy,” Inflammatory Bowel Diseases, vol. 7, no. 4, pp. 328–337, 2001. View at Publisher · View at Google Scholar
  31. M. J. Wagtmans, H. W. Verspaget, C. B. H. W. Lamers, and R. A. van Hogezand, “Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease,” The American Journal of Gastroenterology, vol. 92, no. 9, pp. 1467–1471, 1997. View at Google Scholar · View at Scopus
  32. F. W. Nugent and M. A. Roy, “Duodenal Crohn's disease: an analysis of 89 cases,” The American Journal of Gastroenterology, vol. 84, no. 3, pp. 249–254, 1989. View at Google Scholar · View at Scopus
  33. N. J. Talley, M. T. Abreu, J. Achkar et al., “An evidence-based systematic review on medical therapies for inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 106, no. 1, pp. S2–S25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G. van Assche, A. Dignass, W. Reinisch et al., “The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 63–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. O. H. Nielsen, G. Rogler, D. Hahnloser, and O. Ø. Thomsen, “Diagnosis and management of fistulizing Crohn's disease,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 6, no. 2, pp. 92–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. L. H. Bernstein, M. S. Frank, L. J. Brandt, and S. J. Boley, “Healing of perineal Crohn's disease with metronidazole,” Gastroenterology, vol. 79, no. 2, pp. 357–365, 1980. View at Google Scholar · View at Scopus
  37. Y. Maeda, S. C. Ng, P. Durdey et al., “Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease,” The British Journal of Surgery, vol. 97, no. 9, pp. 1340–1347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. P. J. Tozer, D. Burling, A. Gupta, R. K. S. Phillips, and A. L. Hart, “Review article: medical, surgical and radiological management of perianal Crohn's fistulas,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 1, pp. 5–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K. T. Thia, U. Mahadevan, B. G. Feagan et al., “Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study,” Inflammatory Bowel Diseases, vol. 15, no. 1, pp. 17–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. R. L. West, C. J. van der Woude, B. E. Hansen et al., “Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 11-12, pp. 1329–1336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Dejaco, M. Harrer, T. Waldhoer, W. Miehsler, H. Vogelsang, and W. Reinisch, “Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 11-12, pp. 1113–1120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. D. H. Present, P. Rutgeerts, S. Targan et al., “Infliximab for the treatment of fistulas in patients with Crohn's disease,” The New England Journal of Medicine, vol. 340, no. 18, pp. 1398–1405, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. B. E. Sands, F. H. Anderson, C. N. Bernstein et al., “Infliximab maintenance therapy for fistulizing Crohn's disease,” The New England Journal of Medicine, vol. 350, no. 9, pp. 876–885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. J. I. Fortea-Ormaechea, Y. González-Lama, B. Casis et al., “Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience,” Gastroenterologia y Hepatologia, vol. 34, no. 7, pp. 443–448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. D. R. Topstad, R. Panaccione, J. A. Heine, D. R. E. Johnson, A. R. MacLean, and W. D. Buie, “Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience,” Diseases of the Colon and Rectum, vol. 46, no. 5, pp. 577–583, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Tanaka, K. Matsuo, T. Sasaki et al., “Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?” Hepato-Gastroenterology, vol. 57, no. 97, pp. 3–7, 2010. View at Google Scholar · View at Scopus
  47. C. Hassan, A. Zullo, V. de Francesco et al., “Systematic review: endoscopic dilatation in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 26, no. 11-12, pp. 1457–1464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. G. Rogers and V. L. Katz, “Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review,” The American Journal of Perinatology, vol. 12, no. 4, pp. 262–264, 1995. View at Google Scholar · View at Scopus
  49. M. S. Cappell, V. J. Colon, and O. A. Sidhom, “A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups,” Digestive Diseases and Sciences, vol. 41, no. 12, pp. 2353–2361, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. R. O. Rajapakse, B. I. Korelitz, J. Zlatanic, P. J. Baiocco, and G. W. Gleim, “Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 95, no. 3, pp. 684–688, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Teruel, A. L. S. Román, F. Bermejo et al., “Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines,” The American Journal of Gastroenterology, vol. 105, no. 9, pp. 2003–2008, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ben-Horin and Y. Chowers, “Review article: loss of response to anti-TNF treatments in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 9, pp. 987–995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Baert, M. Noman, S. Vermeire et al., “Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease,” The New England Journal of Medicine, vol. 348, no. 7, pp. 601–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. G. van Assche, C. Magdelaine-Beuzelin, G. D'Haens et al., “Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial,” Gastroenterology, vol. 134, no. 7, pp. 1861–1868, 2008. View at Publisher · View at Google Scholar · View at Scopus